secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001104659-23-101394
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reports positive kidney biopsy results from Phase 2 ELX-02 trial in Alport syndrome
--------------------------------------------------------------------------------

- Three patients showed improvement in foot process effacement on TEM kidney biopsies after 8 weeks of ELX-02 treatment.
- Patient 4401-02 achieved remission based on Urine-Protein Creatine Ratio (UPCR).
- Patient 4402-01 showed wider intact foot process areas, though pre/post comparison was limited.
- Company to seek FDA alignment on pivotal trial design and Breakthrough Therapy Designation for ELX-02.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923101394/0001104659-23-101394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923101394/tm2326310d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-101394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer